Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 0006-0477; 0006-3603; 50090-1085; 65977-0049; 82982-055; 17381-749; 0006-0227; 53002-1686; 71205-777; 68071-2113; 0006-3080; 0006-0473
UNII 22VKV8053U
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Amnestic disorder19.20.05.001; 17.03.02.0070.001648%Not Available
Erectile dysfunction19.08.04.001; 21.03.01.0070.003626%
Renal injury20.01.03.015; 12.01.05.0010.003626%Not Available
Ill-defined disorder08.01.03.0490.004120%Not Available
Disease recurrence08.01.03.0500.001648%Not Available
Renal impairment20.01.03.0100.006098%Not Available
Sinus disorder22.04.06.0020.005604%
Chronic kidney disease20.01.03.0170.002472%
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.009889%Not Available
Suicidal behaviour19.12.01.006--Not Available
Treatment failure08.06.01.0170.008570%Not Available
Low birth weight baby18.04.02.0030.006098%Not Available
Head and neck cancer16.16.01.0030.002472%Not Available
Hypertransaminasaemia09.01.02.0050.001648%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.011537%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.008240%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.002472%
Ureterolithiasis20.04.03.0030.001648%Not Available
Alopecia areata23.02.02.008; 10.04.02.0110.003296%Not Available
Vesicoureteric reflux20.03.05.0020.001648%Not Available
Multiple-drug resistance08.06.01.0320.002472%Not Available
Pyelocaliectasis20.01.06.0110.002472%Not Available
Cerebral calcification17.11.01.0120.001648%Not Available
Lenticulostriatal vasculopathy24.03.05.013; 18.04.04.009; 17.08.02.0220.001648%Not Available
Poor feeding infant18.04.06.006; 14.03.02.0220.001648%Not Available
Gait inability17.02.05.069; 08.01.02.0110.001648%Not Available
Hydrocalyx20.01.05.0050.001648%Not Available
Inhibitory drug interaction08.06.03.0140.001648%Not Available
Kidney perforation20.01.02.0200.001648%Not Available
Renal hypertrophy20.01.06.0170.002472%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene